Three white-matter pathways identified as key to lasting depression relief via DBS

A Mount Sinai research team evaluated the biggest combined sample of individuals treated with subcallosal cingulate deep-brain stimulation for severe, treatment-resistant depression. By modeling electrical fields and applying brain-connectivity maps, they discovered that sustained clinical response required stimulation of three specific white-matter tracts: the cingulum bundle, forceps minor, and the medial uncinate fasciculus/ventral amygdalofugal pathway.

Across several study sites, non-responders after two years shared a common shortfall: inadequate activation of the left cingulum bundle, highlighting how millimeter differences in electrode placement can alter outcomes. The results reinforce a connectome-based targeting approach that is already guiding the randomized Abbott TRANSCEND trial. investigators noted that precise targeting is necessary but not sufficient; patient-specific factors and ongoing stimulation settings also matter, prompting calls for further imaging and personalization research. Funding came from the NIH BRAIN Initiative, the Hope for Depression Research Foundation and the DANA Foundation, with several authors serving as consultants to Abbott Laboratories.